Triovance is a late-preclinical stage biotechnology company transforming the treatment of diabetic foot disease. Its lead product, TRV-01, is a genetically engineered skin substitute, genetically modified to deliver insulin and VegF directly to the site of injury to enhance blood flow and improve cellular regeneration. Unlike traditional treatments, Triovance offers a low-cost, non-invasive, scalable solution that enables outpatient care to cure diabetic foot disease from within with minimal disruption to patients’ lives. Visit www.triovance.com